Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat

The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of disease progression/death was evaluated. AETHERA included 329 Hodgkin lymphoma patients at increase...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2018-01, Vol.59 (1), p.69-76
Main Authors: Gautam, Ashish, Zhu, Yanyan, Ma, Esprit, Lee, Shih-Yuan, Zagadailov, Erin, Teasell, Jeremy, Richhariya, Akshara, Bonthapally, Vijayveer, Huebner, Dirk
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic Agents, Immunological - therapeutic use
Brentuximab vedotin
CD30
Combined Modality Therapy
Consolidation Chemotherapy
Disease Progression
Female
Hematopoietic Stem Cell Transplantation
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Hodgkin Disease - pathology
Hodgkin lymphoma
Humans
Immunoconjugates - therapeutic use
Intention to Treat Analysis
Male
Middle Aged
Neoplasm, Residual - pathology
numbers needed to treat
Proportional Hazards Models
Risk Factors
Transplantation, Autologous
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The number needed to treat (NNT) with brentuximab vedotin consolidation therapy post-autologous stem cell transplant (ASCT) versus placebo in the phase 3 AETHERA trial to avoid one additional event of disease progression/death was evaluated. AETHERA included 329 Hodgkin lymphoma patients at increased risk of progression post-ASCT who received brentuximab vedotin 1.8 mg/kg (n = 165) or placebo (n = 164) on day 1 of each 21-d cycle (up to 16 cycles). Over 60 months, the NNT with brentuximab vedotin ranged from 4.08 to 7.79 for the intent-to-treat population, 3.18-6.07 for patients with ≥2 risk factors, and 2.98-5.65 for patients with ≥3 risk factors. At various time points, and dependent on the risk group, 3-8 patients would need to be treated with brentuximab vedotin consolidation therapy to prevent a disease progression/death, compared with placebo. Patients with increased risk of relapse may benefit most from brentuximab vedotin.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2017.1324160